How Often Should You Get Blood Tests?
Testing too rarely misses problems. Testing too often wastes resources. This guide provides evidence-based frequency recommendations for every major blood test, tailored to your risk level.
Understanding Testing Frequency
Blood test frequency depends on three factors: your baseline health, your personal risk factors, and whether you are monitoring an existing condition or treatment. A healthy 25-year-old with no family history needs far less frequent testing than a 55-year-old with diabetes and hypertension.
This guide uses three tiers: Baseline (healthy adults, no risk factors), Elevated Risk (risk factors present or borderline results), and Active Monitoring (diagnosed condition or on treatment). We also list specific triggers \u2014 symptoms or events that should prompt immediate testing regardless of when your last test was.
The single most important principle is trend tracking. A single blood test result tells you very little. Two or more results over time reveal whether your values are stable, improving, or declining \u2014 and that trend is far more clinically meaningful than any individual number.
Testing Frequency by Panel
Each section covers a major blood test category with recommended frequencies for healthy adults, elevated risk, and active monitoring.
Full Blood Count (FBC)
Baseline (Healthy Adults)
Every 1–2 years for healthy adults with no known conditions. The FBC is the foundation of most blood panels and provides a snapshot of your blood cell production and immune function. Australian GPs routinely include it with any pathology request, so most adults are tested at least every 2 years during routine health checks. It is one of the cheapest tests available and is always bulk-billed.
Elevated Risk
Every 6–12 months if you have a history of anaemia, chronic fatigue, autoimmune disease, or any condition affecting bone marrow function. Women with heavy menstrual periods should have FBC and iron studies at least annually to catch iron deficiency anaemia early, as haemoglobin can drop significantly between yearly checks.
Active Monitoring (On Treatment)
Every 3–6 months if you are on chemotherapy, immunosuppressive medications, anticoagulants, or being treated for a haematological condition. Methotrexate (used for rheumatoid arthritis and psoriasis) requires regular FBC monitoring as it can suppress bone marrow. Your specialist will specify the exact frequency.
Test Sooner If...
Unexplained fatigue or weakness, unusual bruising or bleeding, recurrent infections, pale skin or shortness of breath on exertion, any new medication that affects blood cells, or significant dietary changes (e.g., switching to a vegan diet).
Lipid Panel (Cholesterol)
Baseline (Healthy Adults)
Every 2–5 years for healthy adults aged 20–45 with no cardiovascular risk factors. The RACGP recommends lipid screening from age 45 for men and 55 for women as part of the absolute cardiovascular risk assessment, though testing earlier is wise if there is any family history of heart disease. High cholesterol causes no symptoms whatsoever until it triggers a heart attack or stroke, making regular screening essential.
Elevated Risk
Annually if your total cholesterol exceeds 5.5 mmol/L, LDL exceeds 3.5 mmol/L, or your absolute cardiovascular risk score is moderate to high. Also test annually if you have diabetes, hypertension, a BMI over 30, or a family history of premature cardiovascular disease (heart attack before 55 in a male relative or 65 in a female relative). These risk factors are cumulative — the more you have, the more important annual monitoring becomes.
Active Monitoring (On Treatment)
Every 3–6 months when starting or adjusting lipid-lowering medication (statins, ezetimibe, PCSK9 inhibitors). Once stable on treatment, every 6–12 months is typically sufficient. Your GP or cardiologist will also want to monitor liver function (ALT) while on statins. After a cardiovascular event (heart attack, stent, bypass), monitoring may be more frequent as targets are stricter (LDL below 1.8 mmol/L).
Test Sooner If...
New diagnosis of diabetes or hypertension, starting a statin or other lipid-lowering drug, significant weight gain, change to a high-saturated-fat diet, family member diagnosed with familial hypercholesterolaemia, or planning to start testosterone replacement therapy (which can affect lipid profile).
HbA1c & Glucose (Diabetes Screening)
Baseline (Healthy Adults)
Every 3 years from age 35 for all adults (RACGP guideline). Earlier if you have a BMI over 25, a family history of type 2 diabetes, a history of gestational diabetes, or are of Aboriginal, Torres Strait Islander, South Asian, or Pacific Islander descent — populations with significantly higher diabetes prevalence. In Australia, approximately 1.3 million people have diagnosed type 2 diabetes and an estimated 500,000 are undiagnosed.
Elevated Risk
Annually if your HbA1c is between 42–47 mmol/mol (6.0–6.4%), indicating pre-diabetes. This is the window where lifestyle changes (diet, exercise, weight management) can prevent or delay progression to type 2 diabetes. Fasting insulin is a more sensitive early marker than glucose — it rises years before glucose becomes abnormal. If your fasting insulin exceeds 10 mIU/L or HOMA-IR exceeds 2.0, annual monitoring is warranted.
Active Monitoring (On Treatment)
Every 3 months for people with diagnosed diabetes (type 1 or type 2) who are adjusting medication, insulin, or making significant lifestyle changes. Once HbA1c is stable and at target (typically below 53 mmol/mol or 7.0%), every 6 months may be sufficient. Your endocrinologist or diabetes educator will set your individual target and monitoring schedule based on your age, complications, and treatment plan.
Test Sooner If...
Unexplained increased thirst, frequent urination, blurred vision, slow wound healing, tingling in hands or feet, unexplained weight loss (type 1) or difficulty losing weight (type 2), dark patches on skin folds (acanthosis nigricans), or new diagnosis of PCOS.
Thyroid Function (TSH, Free T4)
Baseline (Healthy Adults)
Every 5 years for adults with no symptoms or risk factors. Thyroid disease is common in Australia, affecting approximately 1 in 20 people, and is 5–8 times more common in women. A single TSH test is a highly effective screen — if normal, it reliably excludes significant thyroid dysfunction. Testing can begin in your 20s if there is a family history of thyroid disease, or in your 30s for women (when autoimmune thyroid disease most commonly presents).
Elevated Risk
Every 12 months if you have subclinical hypothyroidism (TSH mildly elevated, Free T4 normal), positive thyroid antibodies (Hashimoto’s), a goitre, a history of thyroid nodules, or a first-degree relative with autoimmune thyroid disease. Also annually if you have type 1 diabetes, coeliac disease, or other autoimmune conditions, as autoimmune diseases frequently co-occur.
Active Monitoring (On Treatment)
Every 6–8 weeks when starting or adjusting thyroid medication (levothyroxine). Once the dose is stable and TSH is within the target range, monitoring every 6–12 months is standard. During pregnancy, thyroid function should be checked at the first prenatal visit and every 4–6 weeks through the first half of pregnancy, as requirements increase significantly.
Test Sooner If...
Unexplained fatigue, weight gain or difficulty losing weight, feeling cold all the time, hair loss, dry skin, constipation, depression, or conversely — unexplained weight loss, anxiety, tremor, rapid heartbeat, and heat intolerance. Also after pregnancy (postpartum thyroiditis affects up to 10% of women), starting lithium or amiodarone, or receiving neck radiation.
Iron Studies & Ferritin
Baseline (Healthy Adults)
Annually for menstruating women, every 2–3 years for men and post-menopausal women. Iron deficiency is the most common nutritional deficiency worldwide and affects up to 20% of Australian women of reproductive age. Ferritin is the most sensitive marker of iron stores — it drops before haemoglobin becomes abnormal, allowing early detection and treatment before full-blown anaemia develops. For men, the risk reverses — hereditary haemochromatosis (iron overload) affects 1 in 200 Australians of Northern European descent.
Elevated Risk
Every 6–12 months if you have a history of iron deficiency, heavy menstrual periods, a vegan or vegetarian diet, coeliac disease, inflammatory bowel disease, or are an endurance athlete (foot-strike haemolysis can deplete iron). Also every 6–12 months if ferritin has been elevated, to monitor for haemochromatosis or chronic inflammation. Ferritin is an acute-phase reactant and rises with infection and inflammation — if elevated, request CRP simultaneously to determine whether it is a true reflection of iron stores.
Active Monitoring (On Treatment)
Every 3–6 months when actively treating iron deficiency (oral supplements or IV iron infusion). Ferritin should rise by approximately 30–50 µg/L in the 4–8 weeks following an IV iron infusion. Once ferritin is replete (above 50 µg/L, ideally above 100 µg/L for women with heavy periods), recheck every 6–12 months. For haemochromatosis patients undergoing venesection, ferritin is checked at each treatment to guide phlebotomy frequency.
Test Sooner If...
Fatigue not explained by sleep or stress, breathlessness on exertion, pale skin, restless legs, pica (craving non-food items like ice or soil), hair loss, brittle nails, frequent infections, starting an intense exercise programme, major dietary changes, or pregnancy (iron requirements double).
Liver Function Tests (LFTs)
Baseline (Healthy Adults)
Every 2–3 years for healthy adults who drink alcohol infrequently and take no regular medications. Non-alcoholic fatty liver disease (NAFLD) now affects an estimated 5.5 million Australians (approximately 1 in 3 adults) and is strongly associated with obesity, insulin resistance, and metabolic syndrome. NAFLD causes no symptoms until advanced, and liver function tests are the primary screening tool. GGT is particularly sensitive to alcohol intake and metabolic liver disease.
Elevated Risk
Annually if you consume more than 10 standard drinks per week, have a BMI over 30, have type 2 diabetes or insulin resistance, are taking hepatotoxic medications (paracetamol regularly, statins, methotrexate, certain antibiotics), or have chronic hepatitis B or C. Australia has an estimated 200,000 people living with chronic hepatitis B and 130,000 with hepatitis C, many undiagnosed.
Active Monitoring (On Treatment)
Every 3–6 months if you have confirmed liver disease (NAFLD, alcoholic liver disease, hepatitis), are on hepatotoxic medication, or have recently started a statin. ALT above 3 times the upper limit of normal requires medication review and more frequent monitoring. If you are on methotrexate for autoimmune disease, LFTs are typically checked monthly during dose adjustment and then every 2–3 months once stable.
Test Sooner If...
Right upper abdominal discomfort, unexplained nausea, dark urine, pale stools, jaundice (yellowing of skin or eyes), increased alcohol consumption, starting any new medication, unexplained itching, or a recent diagnosis of metabolic syndrome.
Vitamin D (25-Hydroxyvitamin D)
Baseline (Healthy Adults)
Every 2–3 years for the general population, though seasonal testing matters in Australia. Vitamin D deficiency (below 50 nmol/L) affects approximately 23% of Australian adults, with higher rates in southern states during winter (May–September). People with dark skin, those who cover their skin for cultural or religious reasons, shift workers, and the elderly are at highest risk. Medicare bulk bills vitamin D testing only when there is a documented clinical indication — your GP can include this on the pathology request.
Elevated Risk
Annually for people at higher risk of deficiency: those in southern Australia (Victoria, Tasmania, southern NSW), dark-skinned individuals, people over 60, those who are housebound or institutionalised, people on medications that affect vitamin D metabolism (anticonvulsants, glucocorticoids), and those with malabsorption conditions (coeliac disease, inflammatory bowel disease, gastric bypass). Test in late winter (August–September) to capture your lowest level.
Active Monitoring (On Treatment)
Every 3–6 months when repleting a significant deficiency (below 30 nmol/L). After a loading dose of high-strength vitamin D (typically 3000–4000 IU daily for 6–8 weeks), recheck at 3 months to confirm adequate repletion (target above 75 nmol/L, ideally 75–150 nmol/L). Once replete, recheck every 6–12 months during late winter to ensure maintenance dosing is adequate. For people on osteoporosis treatment, vitamin D should be maintained above 75 nmol/L.
Test Sooner If...
Bone pain or aches (especially thighs and hips), muscle weakness, fatigue, frequent infections, low mood especially in winter, diagnosis of osteoporosis or osteopenia, planning to start osteoporosis treatment, recent fracture from minimal trauma, or starting medications that affect bone metabolism.
Kidney Function (eGFR, Creatinine)
Baseline (Healthy Adults)
Every 3–5 years for healthy adults under 50. Chronic kidney disease (CKD) affects approximately 1 in 10 Australian adults but is completely silent in its early stages — most people with stage 1–3 CKD have no symptoms. eGFR is calculated from creatinine and declines naturally with age (approximately 1 mL/min per year after 40). Tracking the trend over time is far more valuable than any single reading. A urine ACR (albumin-to-creatinine ratio) detects protein in the urine, which is often the first sign of kidney damage.
Elevated Risk
Annually if you have hypertension, diabetes, cardiovascular disease, a BMI over 30, a family history of kidney disease, are of Aboriginal or Torres Strait Islander descent (CKD is 3–5 times more prevalent), regularly use NSAIDs (ibuprofen, naproxen), or have a history of urinary tract infections or kidney stones. Also annually from age 50 for all adults. Diabetes and hypertension together account for approximately 60% of all CKD cases in Australia.
Active Monitoring (On Treatment)
Every 3–6 months if you have confirmed CKD (eGFR below 60 mL/min), proteinuria (ACR above 3 mg/mmol), or are on medications that affect kidney function (ACE inhibitors, ARBs, NSAIDs, lithium, some chemotherapy agents). More frequent monitoring is needed if eGFR is declining faster than 5 mL/min per year, which may indicate progressive kidney disease requiring specialist referral.
Test Sooner If...
Foamy or dark urine, swelling in the ankles or around the eyes, unexplained high blood pressure, fatigue, frequent urination (especially at night), loss of appetite, muscle cramps, starting a new medication that is renally excreted, or a recent episode of severe dehydration or acute illness.
Quick Reference Table
A condensed view of testing frequency by risk category. Print this for your records.
| Test | Low Risk | Moderate Risk | High Risk / On Treatment |
|---|---|---|---|
| Full Blood Count | Every 1–2 years | Every 6–12 months | Every 3–6 months |
| Lipid Panel | Every 2–5 years | Annually | Every 3–6 months |
| HbA1c / Glucose | Every 3 years | Annually | Every 3 months |
| Thyroid (TSH) | Every 5 years | Annually | Every 6–8 weeks* |
| Iron / Ferritin | Every 2–3 years | Every 6–12 months | Every 3–6 months |
| Liver Function | Every 2–3 years | Annually | Every 3–6 months |
| Vitamin D | Every 2–3 years | Annually (winter) | Every 3–6 months |
| Kidney (eGFR) | Every 3–5 years | Annually | Every 3–6 months |
* Every 6\u20138 weeks when adjusting thyroid medication dose; every 6\u201312 months once stable. All frequencies are general guidelines \u2014 your doctor may recommend different intervals.
Related Reading
Never Lose Track of Your Test Schedule
Upload your blood test results to SmarterBlood and our AI will track when each marker was last tested, highlight overdue tests, and show trends over time \u2014 completely free.
SmarterBlood provides health information and AI-powered blood test analysis. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health or testing schedule.